Heart Failure

August 18, 2021

The approval of empagliflozin for reducing risk of CV death and hospitalization for heart failure in patients with HFrEF comes less than a year after results of EMPEROR-Reduced were presented at ESC 2020.

August 17, 2021

A recent analysis of health care spending data suggests nearly 1-in-6 heart failure patients forgo or delay care, while also suggesting delaying care ultimately increased healthcare spending by more than $8,000.

August 12, 2021

Data from a major registry suggests more than 90% of patients with heart failure with reduced ejection were discharged from the hospital without being prescribed sacubitril/valsartan (Entresto) and more than 90% of those patients never filled a prescription in the year following hospitalization.

August 10, 2021

Analysis of the GWTG-HF registry demonstrates the efficacy of sacubitril/valsartan in real-world settings. Study investigator Stephen Greene, MD, offers further perspective on the topic in an interview.

July 31, 2021

July's month in review features stories related to EMPEROR-Preserved meeting primary endpoint, a Q&A with Javed Butler, MD, on heart failure prevention, comparing ACEs vs ARBs, and more. Check back around the end of each month for the next Cardiology Month in Review.

July 28, 2021

Despite the notion they are unsafe, a pair of studies demonstrate there were no significant differences in outcomes among heart transplant recipients receiving a donor heart based on a history of illicit drug use or overdose.

July 27, 2021

Practical Cardiology sat down with Javed Butler, MD, following his presentation at ASPC 2021 to discuss how recent advances have impacted prevention of heart failure and how he views the role of primary care/internal medicine in primary prevention.

July 24, 2021

Data from a prespecified analysis of DAPA-CKD examining effects of dapagliflozin in patients with stage 4 CKD suggests the impact of the SGLT2 inhibitor in these patients was similar to those seen in the overall trial.

July 22, 2021

Analysis of more than 40k Medicare beneficiaries suggests increased physical activity, whether it occurs as part of a rehabilitation or not, was associated with decreased risk of all-cause mortality and hospitalizations for heart failure in patients who recently received an implantable cardioverter-defibrillator.

July 15, 2021

From 2008 to 2018, the rate of methamphetamine-associated heart failure hospitalizations in California has risen by nearly 600% while the costs associated with these events has risen by more than 800% during that same time frame.